LILRA6抗体;LILRA6 Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using LILRA6 mouse mAb (green) and negative control (red).    

  
  

The leukocyte immunoglobulin-like receptor subfamily A member 6 (LILRA6), also known as ILT8 or CD85g, is a cell surface receptor belonging to the LILR family, which regulates immune responses by interacting with MHC class I molecules. LILRA6 is primarily expressed on myeloid cells, including monocytes, macrophages, and dendritic cells, and exists in both membrane-bound and soluble forms due to alternative splicing. Unlike other activating LILRs, LILRA6 lacks a canonical signaling motif but may modulate immune activation through interactions with signaling adaptor proteins or by competing with inhibitory receptors for ligand binding. Its exact ligands and downstream pathways remain poorly characterized, though it is hypothesized to recognize conserved regions of MHC class I or pathogen-associated molecules.

Research on LILRA6 antibodies focuses on their utility in detecting receptor expression in immune cells and dissecting its functional roles. Dysregulation of LILRA6 has been implicated in autoimmune diseases, chronic inflammation, and cancer, where altered receptor expression may influence immune evasion or hyperactivation. Antibodies targeting LILRA6 are essential tools for immunohistochemistry, flow cytometry, and functional studies to explore its involvement in disease pathogenesis. Additionally, therapeutic antibodies or antagonists are being investigated for modulating LILRA6 activity in conditions like rheumatoid arthritis or malignancies. Despite progress, further studies are needed to clarify its ligand specificity, signaling mechanisms, and therapeutic potential.